A review of analytical method development and validation of labetalol hydrochloride

Combined alpha- and beta-adrenoceptor blockers, such as labetalol hydrochloride, are administered orally
and intravenously to treat hypertension. It is a competitive antagonist of postsynaptic nascent 1-
adrenoceptors and an unselective antagonist of beta-adrenoceptors. It is a medication used to treat
hypertension. A significant amount of research has been conducted on the synthesis, pharmacology,
mechanism of action, and other aspects of labetalol hydrochloride. However, the authors of this paper
have only addressed the analytical methodologies that have been published, thus far for the estimation of
labetalol hydrochloride in pharmaceutical dosage forms. Reviewing various analytical techniques and
validating the related substance of labetalol hydrochloride is the main goal of this article.